Lirum Therapeutics announced it raised $6.3 Million in an initial filing from an offering of $10 Million

Company

Location

About

Lirum Therapeutics is an innovative biopharmaceutical company focused on the treatment of debilitating diseases through the acquisition, development and commercialization of novel drug candidates with compelling mechanisms of action, regulatory pathways and commercial opportunities. ​ Our goal is to build a leading biopharmaceutical company focused on improving the lives of patients with difficult-to-treat diseases by developing and commercializing novel first-in-class therapeutics. ​ The company was created by Stemline Therapeutics (formerly NASDAQ: STML) management, a veteran team with a proven track record of clinical and regulatory achievement, including FDA and EMA approval and the successful commercial launch of ELZONRIS®, an FDA-designated breakthrough therapy, for an orphan malignancy based on an innovative trial design. The team also has a record of significant value creation. ​ Lirum was founded in 2021 and is headquartered in New York City.